Presentation from first AMiCI Action update given by Minna and Francy through the virtual HILL system on Feb 1st 2018.

1. Virtual update for AMiCI contacts
Francy Crijns (Chair) – Minna Keinänen-Toivola (Vice-Chair)
1st February 2018
AntiMicrobial
Coating Innovations

2. • Chair of the Action
Dr. Francy Crijns
Zuyd University of Applied Sciences, NL
francy.crijns@zuyd.nl
• Vice-Chair of the Action
Dr. Minna Keinanen-Toivola
Satakunta Univ. App. Sciences, FI
minna.keinanen-toivola@samk.fi

3. Anti-MIcrobial Coating Innovations to prevent
infectious diseases (AMiCI)
2016-2020
Objectives
• To evaluate the impact of (introducing) AntiMicrobial
Coatings in healthcare on the spread of infections and on
the efficacy in fighting HealthCare Associated Infections
(HAI) and bacterial resistance to current antibiotics.
• To stimulate collaboration between industry and research
institutes using available knowledge, and disclose state of-
the- art nanotechnology and biotechnology knowledge, to
industrial partners.
• To develop, structure, coordinate and maintain a long-
term, flexible and open European network in the field of
AMC in healthcare.

4. AMiCI
Investigate new methods of
effective cleaning, additional
to the use of AMCs to ensure a
safe and more hygienic future
AMiCI Action Strategy
Focus on (eco)toxicological
risks and possible introduction
of AMR resulting from the use
of AMC
Development of lab and field
benchmark tests to evaluate
efficacy and efficiency of
AMCs to reduce bacterial
contamination in the
environment of
patients in healthcare
Reaching a conceptual
understanding of the
mechanisms and construction
of an active and sustainable
coating, to adapt current
and develop new
coatings to meet
ECHA standards
WG1
AM Materials
Safe-by-Design
WG2
Performance
Assessment
(lab-field-
benchmark)
WG4
The New
Cleaning
WG3
Adverse
Effects/ Risk
Benefit
Analysis

5. WG1 – Antimicrobial Coatings – Safe by Design
Dr. Hülya Olmez TUBITAK MRC Food Institute, Turkey WG Leader
Dr. Nuno Azevedo University of Porto, Portugal WG Vice Leader
WG2 – Performance Assessment of Antimicrobial Coatings
Pete Askew IMSL, United Kingdom WG Leader
Dr. Birgit Teunissen Zuyd University of Applied Sciences, The Netherlands WG Vice Leader
WG3 - Adverse Effects of Antimicrobial Coatings
Dr. Anne Kahru Institute of Chemical Physics and Biophysics, Estonia WG Leader
Dr. Merja Ahonen Satakunta University of Applied Sciences, Finland WG Vice Leader
WG4 – The new cleaning
Dr. Martina Modic Jozef Stefan Institute, Slovenia WG Leader
Prof. Dr. Colum Dunne University of Limerick, Ireland WG Vice Leader
WG5 – Communication and dissemination
Kazimierz Murzyn LifeScience Krakow Klaster, Poland WG Leader
Dr. Theofilos Papadopoulos Aristoteles University of Thessaloniki, Greece WG Vice Leader

6. Status of the Action
Parties
Country Date Country Date Country Date Country Date
Austria 28/08/2017
Belgium 21/12/2015 Bulgaria 05/01/2016 Croatia 20/04/2016 Czech
Republic
13/09/2016
Denmark 07/01/2016 Estonia 18/11/2015 Finland 24/11/2015 France 06/01/2016
Germany 24/11/2015 Greece 04/12/2015 Ireland 21/12/2015 Israel 09/12/2015
Italy 26/01/2016 Latvia 28/04/2016 Lithuania 05/01/2016 Malta 28/11/2015
Netherlands 26/11/2015 Norway 12/09/2016 Poland 12/02/2016 Portugal 22/01/2016
Romania 10/12/2015 Serbia 04/01/2016 Slovenia 11/01/2016 Spain 13/01/2016
Sweden 06/10/2016 Switzerland 21/01/2016 Turkey 20/02/2016 United
Kingdom
17/11/2015
fYR
Macedonia
22/12/2015 Montenegro 19/01/2018
Total: 31
COST International Partner Country: 1
Center for Biofilm Engineering – United States of America

7. Activities
• Meetings – Conferences – Workshops
• STSMs
• Publications
• Website

8. Heerlen Meetings – November 2016

9. Goal, setup & outcome
• MC & CG meeting: organizational and strategic
• Presentations of 4 WG topics (recordings see :
http://amici.lifescienceopenspace.pl/first-amici-working-group-
meetings-in-heerlen-a-great-success/ )
• World café: discussion on WG topics in multidisciplinary groups
• Publications:

10. Publications from Heerlen World cafe:
• WG1: Surface modifications for antimicrobial effects in the healthcare
setting: a critical overview; Adlhart C. et al. accepted Journal of Hospital
Infection (2018)
• WG2: in preparation
• WG3: Proactive Approach for Safe Use of Antimicrobial Coatings in
Healthcare Settings: Opinion of the COST Action Network AMiCI; Ahonen
M, Kahru A et al. International journal of environmental research and
public health (2017)
• WG4: Antimicrobial coatings for reduction of hospital acquired infection
and associated specialised cleaning: Opinion of the COST Action Network
AMiCI (CA15114); Dunne C. et al. submitted to the Journal of Hospital
Infection

12. “Antimicrobial Coatings in Health Care:
from Innovations to the Market”
• Day 1: keynote speakers
• Day 2: management committee meeting, WG meetings
• Over 60 participants, 21 countries (researchers, companies, less
regulators)
-> For a coating to enter market registration can be the bottle neck
-> Need for wide risk-benefit analysis (WG3)
-> Need to benchmark cleaning procedures
http://www.samk.fi/en/uutiset/the-international-amici-conference-
hosted-by-samk-was-a-success/
• Day1: https://www.youtube.com/watch?v=Fl27Ojptg8U
• Day 2: https://www.youtube.com/watch?v=xIZIgu5OOQk

13. AMiCI WG3 Workshop
Tallinn (EE), 16-17 November 2017

14. • National Institute of Chemical Physics and Biophysics,
Tallinn, Estonia
• Topic: development and spreading microbial
antibiotic resistance
• Audience: 25 AMICI members + dozen Estonian
researchers and students took part
• Lecturers:
• Prof. T. Tenson, Prof. I. Lutsar, Dr. P. Märtin, Dr. S.
Kõljalg*, dr T. Papadopolous*, Dr. O.M. Pereira, Dr.
M. Riool*)
*AMICI members
• The slides of the talks are on AMICI website
• The information on the successful Meeting was
published on Estonian Research Agency Website (in
Estonian) and on AMICI website (in English).

15. Day 2 afternoon
Roundtable & interactive discussion
• Conclusions
• No common global rules or acceptance schemes for AMCs are available.
Generally accepted global rules are needed to enable customers/ buyers/
end-users to evaluate the efficacy, safety and cost-benefits of various
products using AMC, and to minimize the risks of AMR development during
usage and disposal of the products.
• efficacy? one test method for all materials, clinical real-life studies are needed
• safety?
• environmental aspects?
• Biocide regulation as a partial answer to the need above?
• The “rules” in food & textile industry could be adopted with suitable parts to
AMCs used in inanimate surfaces of healthcare settings

16. STSMs
• 4 in GP1
• 6 in GP2:
• WG1: Evaluating the anti-biofilm activity of surfaces composed of ZnO/Ag
heterostructures (completed in Porto)
• WG1: Fabrication of electrospun antimicrobial nanofibers based on
phytochemicals (to be performed in Zurich)
• WG2: Antibacterial coatings on dental surfaces/implants (to be performed in
Italy)
• WG2: Development of lab based simulation tests (to be performed in Geleen)
• WG3: Development of an inventory on dissolution-driven environmental
effects of AMC-related nanoparticles (to be performed in Tallinn)
• WG4: Standard operating procedures in cleaning (?)

17. What did we learn?
• Many research laboratories are developing coatings to be used in
healthcare settings
• Not that many coatings available for hard surfaces in healthcare
• Few pilot studies with AMCs in patient rooms

18. Upcoming meetings

19. Further issues
• ECI’s
• ITC conference grants
• News from AMiCI members, announcements, publications 
AMiCI website www.amici-consortium.eu
contact person: Kazimierz Murzyn (kmurzyn@lifescience.pl)
• Grant opportunities
• Other issues?
• How did you experience virtual meeting?